• Wei-Chun Huang, Chih-Hsin Hsu, Shih-Hsien Sung, Wan-Jing Ho, Chun-Yuan Chu, Chih-Ping Chang, Yu-Wei Chiu, Chun-Hsien Wu, Wei-Ting Chang, Lin Lin, Shoa-Lin Lin, Chin-Chang Cheng, Yih-Jer Wu, Shu-Hao Wu, Tsu-Yi Hsieh, Hsao-Hsun Hsu, Morgan Fu, Zen-Kong Dai, Ping-Hung Kuo, Juey-Jen Hwang, Shu-Meng Cheng, and TSOC pulmonary hypertension committee.
• Department of Critical Care Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Physical Therapy, Fooyin University, Kaohsiung, Taiwan.
• J Formos Med Assoc. 2019 Dec 1; 118 (12): 1584-1609.

AbstractPulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.Copyright © 2019. Published by Elsevier B.V.

11 keywords...

hide…